Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | HPGDS | O60760 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4585312 | 0.76 | CCR1 (0.43) | MCHR1MAPTTSHRTDP1 | |
| SCHEMBL12926883 | 0.76 | CA2 (0.40) | CA2MCHR1GABRA1GABRB2ALDH1A1 | |
| SCHEMBL10265003 | 0.76 | METAP2 (0.55) | CA2GABRA1GABRB2MAPTTDP1 | |
| SCHEMBL2609306 | 0.76 | AR (0.41) | MCHR1ALDH1A1TSHRTDP1METAP2 | |
| SCHEMBL10199505 | 0.76 | LMNA (0.41) | CA2MCHR1GABRA1GABRB2ALDH1A1 | |
| SCHEMBL23456655 | 0.74 | CCR1 (0.32) | — | |
| SCHEMBL2609299 | 0.74 | XPO1 (0.42) | MCHR1ALDH1A1METAP2 | |
| SCHEMBL29296668 | 0.74 | NCF1 (0.53) | MCHR1 | |
| SCHEMBL22932120 | 0.74 | MCHR1 (0.34) | MCHR1MAPTTSHRTDP1METAP2 | |
| SCHEMBL15077050 | 0.74 | AR (0.40) | MCHR1ALDH1A1MAPTTSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200385402-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | REGENERON PHARMACEUTICALS, INC. | 2020-12-10 | — | — | US | disclosed |
| US-20120141414-A1 | Bimacrocylic HCV NS3 Protease Inhibitors | SEQUOIA PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200385402-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | SLC10A1, HNMT, OGFR | CA2 3421/4885MCHR1 142/4885GABRA1 1910/4885 |
| US-20120141414-A1 | Bimacrocylic HCV NS3 Protease Inhibitors | HAVCR2, CTRC, CTSC | CA2 3367/4885MCHR1 4607/4885GABRA1 3434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.